Opus Genetics IRD
NASDAQ IRD
$4.67 +0.07 (+1.52%)
As of: Sep 4, 2026 · 3:59 PM EDT

Opus Genetics (IRD) EV to CFO (2010 - 2026)

Analysis

Opus Genetics (IRD) EV to CFO (2010 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Opus Genetics 446.86 Mn 358.05 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -20.99
Mar 31, 2026 -20.81
Dec 31, 2025 -9.70
Sep 30, 2025 -12.29
Jun 30, 2025 -2.33
Mar 31, 2025 0.96
Dec 31, 2024 -0.97
Sep 30, 2024 0.45
Jun 30, 2024 0.23
Mar 31, 2024 -0.56
Dec 31, 2023 4.76
Sep 30, 2023 -11.10
Jun 30, 2023 51.62
Mar 31, 2023 -10.84
Dec 31, 2022 1.08
Sep 30, 2022 -6.19
Jun 30, 2022 -5.63
Mar 31, 2022 -6.95
Dec 31, 2021 -5.43
Sep 30, 2021 -18.54